These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17508936)

  • 1. Structure based drug design for HIV protease: from molecular modeling to cheminformatics.
    Volarath P; Harrison RW; Weber IT
    Curr Top Med Chem; 2007; 7(10):1030-8. PubMed ID: 17508936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient molecular docking of NMR structures: application to HIV-1 protease.
    Huang SY; Zou X
    Protein Sci; 2007 Jan; 16(1):43-51. PubMed ID: 17123961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
    Islam MA; Pillay TS
    J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Screening of new HIV inhibitors based on the database of traditional Chinese medicine].
    Gao WN; Li Y; Zhang R; Gao H; Xu WR; Li AX; Du QS; Zhang X; Wei DQ
    Yao Xue Xue Bao; 2006 Mar; 41(3):241-6. PubMed ID: 16758996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mining HIV protease cleavage data using genetic programming with a sum-product function.
    Yang ZR; Dalby AR; Qiu J
    Bioinformatics; 2004 Dec; 20(18):3398-405. PubMed ID: 15256407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virtual Screening for HIV Protease Inhibitors Using a Novel Database Filtering Procedure.
    Takkis K; García-Sosa AT; Sild S
    Mol Inform; 2015 Jun; 34(6-7):485-92. PubMed ID: 27490392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimized Virtual Screening Workflow: Towards Target-Based Polynomial Scoring Functions for HIV-1 Protease.
    Pintro VO; de Azevedo WF
    Comb Chem High Throughput Screen; 2017; 20(9):820-827. PubMed ID: 29165067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in automated docking applied to human immunodeficiency virus type 1 protease.
    Miller MD; Sheridan RP; Kearsley SK; Underwood DJ
    Methods Enzymol; 1994; 241():354-70. PubMed ID: 7854188
    [No Abstract]   [Full Text] [Related]  

  • 9. Improving binding mode predictions by docking into protein-specifically adapted potential fields.
    Radestock S; Böhm M; Gohlke H
    J Med Chem; 2005 Aug; 48(17):5466-79. PubMed ID: 16107145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Database screening for HIV protease ligands: the influence of binding-site conformation and representation on ligand selectivity.
    Schnecke V; Kuhn LA
    Proc Int Conf Intell Syst Mol Biol; 1999; ():242-51. PubMed ID: 10786307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein promiscuity: drug resistance and native functions--HIV-1 case.
    Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
    J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Off-Target-Based Design of Selective HIV-1 PROTEASE Inhibitors.
    La Monica G; Lauria A; Bono A; Martorana A
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34199858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ensemble docking of multiple protein structures: considering protein structural variations in molecular docking.
    Huang SY; Zou X
    Proteins; 2007 Feb; 66(2):399-421. PubMed ID: 17096427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporating protein flexibility in structure-based drug discovery: using HIV-1 protease as a test case.
    Meagher KL; Carlson HA
    J Am Chem Soc; 2004 Oct; 126(41):13276-81. PubMed ID: 15479081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative studies on inhibitors of HIV protease: a target for drug design.
    Jayaraman S; Shah K
    In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A detailed comparison of current docking and scoring methods on systems of pharmaceutical relevance.
    Perola E; Walters WP; Charifson PS
    Proteins; 2004 Aug; 56(2):235-49. PubMed ID: 15211508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple Target Drug Design Using LigBuilder 3.
    Qing X; Wang S; Yuan Y; Pei J; Lai L
    Methods Mol Biol; 2021; 2266():279-298. PubMed ID: 33759133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design.
    Wlodawer A; Vondrasek J
    Annu Rev Biophys Biomol Struct; 1998; 27():249-84. PubMed ID: 9646869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of machine learning to improve the results of high-throughput docking against the HIV-1 protease.
    Klon AE; Glick M; Davies JW
    J Chem Inf Comput Sci; 2004; 44(6):2216-24. PubMed ID: 15554692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multistage virtual screening and identification of novel HIV-1 protease inhibitors by integrating SVM, shape, pharmacophore and docking methods.
    Wei Y; Li J; Chen Z; Wang F; Huang W; Hong Z; Lin J
    Eur J Med Chem; 2015 Aug; 101():409-18. PubMed ID: 26185005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.